MedTrace Logo

Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

NCT04340024 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-06-11

No results posted yet for this study

Summary

Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.

Conditions

Sponsors & Collaborators

  • National Medical Research Council (NMRC), Singapore

    collaborator OTHER_GOV

  • Duke-NUS Graduate Medical School

    collaborator OTHER

  • Ferring Pharmaceuticals

    collaborator INDUSTRY

  • ImmunoSCAPE

    collaborator INDUSTRY

  • Decipher Biosciences

    collaborator UNKNOWN

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Melvin Chua, MD · National Cancer Centre, Singapore

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04340024 on ClinicalTrials.gov